Drug Search Results
Using advanced filters...
Advanced Search [+]

Tranexamic acid

Alternative Names: tranexamic acid, cyklokapron, transamin, exacyl, lysteda, retavase
Clinical Status: Inactive
Latest Update: 2025-07-01
Latest Update Note: Clinical Trial Update

Product Description

Tranexamic acid is used to treat heavy menstrual bleeding in women. This medicine may be used by teenage females, but is not intended for use before the start of menstruation. Tranexamic acid is an antifibrinolytic agent. It works by blocking the breakdown of blood clots, which prevents bleeding. (Sourced from: https://www.mayoclinic.org/drugs-supplements/tranexamic-acid-oral-route/description/drg-20073517)

Mechanisms of Action: Fibrinolysis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral,Topical

FDA Designation: *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Ferring
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tranexamic acid

Countries in Clinic: Croatia, Germany, Hungary, Nigeria, Pakistan, Romania, Spain, Tanzania, United States, Zambia

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Anemia|Brain Hemorrhage, Traumatic|Hip Fracture|Injuries/wounds Unspecified|Sarcoma

Phase 2: Stroke

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2005-005103-41

P2

Completed

Unknown

2025-01-30

2025-05-06

Primary Completion Date|Study Completion Date|Treatments|Trial Status

STOP-MSU

P2

Completed

Stroke

2023-05-28

2025-05-16

Treatments

PRADO

P2

Active, not recruiting

Unknown

2022-05-07

2025-05-06

Treatments

TIC-TOC

P3

Not yet recruiting

Brain Hemorrhage, Traumatic

2030-03-31

2023-11-16

Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments

TATRA

P3

Not yet recruiting

Anemia

2025-11-30

2024-05-15

Primary Endpoints|Treatments

HYL-P004-003

P3

Recruiting

Injuries/wounds Unspecified

2024-12-27

4%

2024-08-02

HYL-P004-003

P3

Recruiting

Injuries/wounds Unspecified

2024-06-27

4%

2025-05-02

Treatments

WOMAN-2

P3

Completed

Anemia

2023-09-20

2024-01-11

NCT05047133

P3

Recruiting

Hip Fracture

2022-07-01

2024-03-06

UTOTXA_2016

P3

Active, not recruiting

Sarcoma

2019-01-31

2022-03-13

Treatments